Hodgkin-Lymphom
Reference20 articles.
1. Ahmed S, Kanakry JA, Ahn KW et al.: Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biol Blood Marrow Transplant 25(9) (2029) 1859–1868. 2. Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al.: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109(5) (2007) 1878–1886. 3. Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al.: Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21(18) (2003) 3431–3439. 4. Behringer K, Goergen H, Hitz F et al.: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385(9976) (2015) 1418–1427. 5. Behringer K, Goergen H, Müller H, et al. Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. J Clin Oncol 34(36) (2016) 4329–4337.
|
|